- Previous Close
1.3000 - Open
1.3000 - Bid 1.2500 x 100
- Ask 1.3200 x 100
- Day's Range
1.2502 - 1.3050 - 52 Week Range
1.1500 - 3.7600 - Volume
122,664 - Avg. Volume
147,017 - Market Cap (intraday)
33.796M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.75
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
www.ocuphire.comRecent News: OCUP
View More
Performance Overview: OCUP
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCUP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCUP
View MoreValuation Measures
Market Cap
33.80M
Enterprise Value
-7.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.86
Price/Book (mrq)
0.83
Enterprise Value/Revenue
0.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-85.75%
Return on Assets (ttm)
-21.35%
Return on Equity (ttm)
-36.01%
Revenue (ttm)
16.45M
Net Income Avi to Common (ttm)
-14.11M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
41.41M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.7M
Research Analysis: OCUP
View MoreCompany Insights: OCUP
OCUP does not have Company Insights